Abstract
Purpose
Few studies have evaluated the chemopreventive effect of aspirin on the cancer risk in elderly women. We examined associations between frequency, dose, and duration of aspirin use with incidence of 719 aspirin-sensitive cancers (cancers of colon, pancreas, breast, and ovaries) in the Iowa Women’s Health Study (IWHS), a prospective cohort of women over 70 years old.
Methods
Aspirin frequency, dose, and duration were self-reported in the 2004 IWHS questionnaire. Women were followed-up to 2011. Cancer cases were ascertained by linkage to the Iowa State Health Registry. Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95 % confidence intervals (CI).
Results
Among the 14,386 women, 30 % were nonusers of aspirin; 34 % used low-dose aspirin, and 36 % used regular- or high-dose aspirin. Compared with nonuse of aspirin, the HRs (95 % CI) for incidence of aspirin-sensitive cancers were 0.87 (0.72–1.06) for regular to high doses of aspirin use, 0.95 (0.80–1.13) for aspirin use 6+ times per week, and 0.93 (0.74–1.17) for aspirin use for 10+ years. For cumulative aspirin use, HR (95 % CI) was 0.87 (0.70–1.09) for >60,000 mg of aspirin per year and 0.95 (0.75–1.21) for >280,000 mg of aspirin in their lifetime, versus nonuse of aspirin. Results were similar for the all-cause cancer death as an endpoint, with a significant inverse association observed between lifetime aspirin dose and cancer mortality [<95,000 mg vs nonuser HR 0.76 (0.61–0.95)].
Conclusions
These findings suggest that aspirin use may prevent incident breast, colon, pancreatic, and ovarian cancer in elderly women.
References
Howlader N, Noone AM, Krepcho M et al (2013) SEER cancer statistics review, 1975–2010. National Cancer Institute. http://seer.cancer.gov/csr/1975_2010/. Accessed 11 Apr 2016
Administration on Aging (2012) A profile of older Americans: 2012. U.S. Department of Health and Human Services, Washington
Suzman R, Willis DP (eds) (1992) Introducing the oldest old. Oxford University Press, New York
Harding C, Pompei F, Wilson R (2009) Peak and decline in cancer incidence, mortality, and prevalence at old ages. Cancer 118(5):1371–1386
Rothwell PM, Fowkes GR, Belch JFF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759):31–41
Anderson KE, Johnson TW, Lazovich D, Folsom AR (2002) Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 94(15):1168–1171
Bardia A, Ebbert JO, Vierkant RA et al (2007) Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 99(11):881–889
Bardia A, Olson JE, Vachon CM et al (2011) Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 126(1):149–155
Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM (2003) Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer 106(5):784–788
Jacobs EJ (2011) Will an aspirin a day help keep fatal cancer away? Lancet 377(9759):3–4
Johnson TW, Anderson KE, Lazovich D, Folsom AR (2002) Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomark Prev 11(12):1586–1591
Prizment AE, Folsom AR, Anderson KE (2010) Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women’s Health Study. Cancer Epidemiol Biomark Prev 19(2):435–442
Thun MJ, Jacobs EJ, Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9(5):259–267
Rose S (2013) A role for aspirin in cancer prevention? Cancer Discov 3(12):1324
Cao Y, Nishihara R, Wu K et al (2016) Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. doi:10.1001/jamaoncol.2015.6396
Rothwell PM, Price JF, Fowkes GR et al (2012) Short-term effectsof daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379(9826):1602–1612
Chubak J, Whitlock EP, Williams SB et al (2016) Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med. doi:10.7326/M15-2117
Siu AL (2016) Preventive Services Task Force. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 164:279–296. doi:10.7326/M15-2886
USPSTF (2008) U.S. Preventive Service Task Force. Screening for colorectal cancer. Current recommendation. http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm. Accessed 12 Jan 2014
Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061–2067
Cuzick J, Otto F, Baron JA et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10(5):501–507
Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13(5):518–527
Bisgard KM, Folsom AR, Hong CP, Sellers TA (1994) Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up. Am J Epidemiol 139:990–1000
WCRF/AICR (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. World Cancer Research Fund/American Institute for Cancer Research, Washington
Inoue-Choi M, Ward MH, Cerhan JR, Weyer PH, Anderson KE, Robien K (2013) Adherence to the WCRF/AICR guidelines for cancer prevention is associated with lower mortality among older female cancer survivors. Cancer Epidemiol Biomark Prev 22(5):792–802
Zhang S, Folsom AR, Sellers TA, Kushi LH, Potter JD (1995) The Iowa Women’s Health Study. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. Cancer 76:275–283
Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C (2012) Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23(6):1403–1415
Mahipal A, Anderson KE, Limburg PJ, Folsom AR (2006) Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa Women’s Health Study. Cancer Epidemiol Biomark Prev 15(10):1785–1790
Trabert B, Ness RB, Lo-Ciganic W et al (2014) Aspirin, non-aspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 106(2):djt431
Baandrup L, Faber MT, Christensen J et al (2013) Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand 92(3):245–255
Zhang YP, Wan YD, Sun YL, Li J, Zhu RT (2015) Aspirin might reduce the incidence of pancreatic cancer: a meta-analysis of observational studies. Sci Rep 5:15460
Qiu W, Chavarro J, Lazarus R, Rosner B, Ma J (2012) powerSurvEpi: power and sample size calculation for survival analysis of epidemiological studies. R package version 0.0.6. http://CRAN.R-project.org/package=powerSurvEpi
R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http://www.R-project.org/
Therneau T, Lumley T (2014) A package for survival analysis in S. R package version 2.37-7. http://CRAN.R-project.org/package=survival
Bardia A, Keenan TE, Ebbert JO et al (2015) Personalizing aspirin use for targeted breast cancer chemoprevention in postmenopausal women. Mayo Clin Proc 91(1):71–80
USPSTF (2016) U.S. Preventive Service Task Force. aspirin use to prevent cardiovascular disease and colorectal cancer: preventive medication. Final update summary http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/aspirin-to-prevent-cardiovascular-disease-and-cancer?ds=1&s=aspirin. Accessed 15 Apr 2016
Cho H, Klabunde C, Yabroff KR et al (2013) Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. Ann Intern Med 159:667–676
ASPREE Investigator Group (2013) Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials 36:555–564
Lazovich D, Robien K, Cutler G, Virnig B, Sweeney C (2009) Quality of life in a prospective cohort of elderly women with and without cancer. Cancer 115(18 suppl):4283–4297
Acknowledgments
This study was supported by National Institutes of Health (NIH) Grant R01 CA039742. AEP was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award UL1TR000114.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Vaughan, L.E., Prizment, A., Blair, C.K. et al. Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women’s Health Study. Cancer Causes Control 27, 1395–1402 (2016). https://doi.org/10.1007/s10552-016-0804-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-016-0804-8